Showing 20 of 206 recruiting trials for “t-cell-prolymphocytic-leukemia”
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
👨⚕️ Christine E Gruessner, M.D., National Heart, Lung, and Blood Institute (NHLBI)📍 1 site📅 Started Jun 2019View details ↗
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
👨⚕️ Matthew J Wieduwilt, Alliance for Clinical Trials in Oncology📍 271 sites📅 Started May 2019View details ↗
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
👨⚕️ Prof. Dr. Michael Schmitt, University Hospital Heidelberg, Department V📍 2 sites📅 Started Sep 2018View details ↗
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
RecruitingNCT03568266 ↗
Pharmacogenomics of Asparaginase Induced Hepatotoxicity
👨⚕️ Houda Alachkar, Ph.D., University of Southern California📍 1 site📅 Started May 2018View details ↗
RecruitingNCT03501576 ↗
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
RecruitingNCT03342144 ↗
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
RecruitingNCT03375619 ↗
Long-term Follow-up Study of Patients Receiving CAR-T Cells
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
👨⚕️ Brenda M. Sandmaier, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Oct 2017View details ↗
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
👨⚕️ Leland Metheny, MD, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center📍 7 sites📅 Started Jul 2017View details ↗
CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
RecruitingNCT03197259 ↗
Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
CARPALL: Immunotherapy with CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →